<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02466659</url>
  </required_header>
  <id_info>
    <org_study_id>IndianU</org_study_id>
    <nct_id>NCT02466659</nct_id>
  </id_info>
  <brief_title>Controlled Intermittent Alternate Occlusion (CIAO) Therapy for Intermittent Exotropia</brief_title>
  <acronym>CIAO</acronym>
  <official_title>A Clinical Trial of Observation Versus Controlled Intermittent Alternate Occlusion (CIAO) Therapy for Intermittent Exotropia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effectiveness of alternate occlusion therapy for the treatment of IXT among
      patients aged 3 to &lt; 11 years old.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intermittent exotropia (IXT) is the most common form of childhood-onset exotropia with an
      incidence of 32.1 per 100,000 in children. Before surgery, many cases of IXT are treated
      using non-surgical interventions, such as part-time alternate occlusion. However, the
      &quot;alternating&quot; occlusion with traditional patches is usually out of control. The investigators
      are uncertain about the amount of &quot;alternating&quot; in patching treatment.

      Here, the investigators introduce controlled intermittent alternating occlusion (CIAO)
      therapy, which is provided by a new electronic device, -liquid crystal glasses. This study is
      to determine the effectiveness of alternate occlusion therapy for the treatment of IXT among
      patients aged 3 to &lt; 11 years old. Children with IXT will be randomized into either an
      observation group or a CIAO therapy group.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    no fund
  </why_stopped>
  <start_date type="Actual">February 1, 2015</start_date>
  <completion_date type="Actual">December 1, 2016</completion_date>
  <primary_completion_date type="Actual">December 1, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Composite Measure of IXT Control Score</measure>
    <time_frame>12 weeks; 24 weeks</time_frame>
    <description>IXT control score: referring to the Pediatric eye disease investigator group (PEDIG).
PEDIG scale of control for IXT 1-5 is defined as the following:
5 = Constant exotropia 4 = exotropia &gt; 50% of the 30-sec period before dissociation 3 = exotropia &lt; 50% of the 30-sec period before dissociation 2 = No exotropia unless dissociated, recovers in &gt; 5 sec
1 = No exotropia unless dissociated, recovers in 1-5 sec 0 = No exotropia unless dissociated, recovers in &lt; 1 sec (phoria) Not Applicable = No exotropia present</description>
  </primary_outcome>
  <other_outcome>
    <measure>Amblyopia</measure>
    <time_frame>3 Months</time_frame>
    <description>It is defined when visual acuity between two eyes equal or over 2 logMAR lines.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Intermittent Exotropia</condition>
  <arm_group>
    <arm_group_label>CIAO Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention with wearing 3-hour daily CIAO therapy glasses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>To observe as one kind of standard care for IXT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CIAO therapy Amblyz glasses</intervention_name>
    <description>3-hour CIAO Therapy Amblyz glasses</description>
    <arm_group_label>CIAO Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Intermittent exotropia (manifest deviation) meeting all of the following criteria:

               -  Intermittent exotropia at distance OR constant exotropia at distance and either
                  intermittent exotropia or exophoria at near

               -  Exodeviation at least 15PD at distance OR near measured by prism and alternate
                  cover test (PACT)

               -  Exodeviation at least 10PD at distance measured by PACT

          -  No previous surgical or non-surgical treatment for IXT (other than refractive
             correction)

          -  Visual acuity in the worse eye 0.3 logMAR or better (20/40 on ATS HOTV or 70 letters
             on E-ETDRS) for children ≥ 3 years of age

          -  No interocular difference of visual acuity more than 0.2 logMAR (2 lines on ATS HOTV
             or 10 letters on E-ETDRS) for children ≥ 7 years of age

          -  Investigator not planning to initiate amblyopia treatment

          -  No hyperopia greater than +3.50 D spherical equivalent in either eye

          -  No myopia greater than -6.00 D spherical equivalent in either eye

          -  No prior strabismus, intraocular, or refractive surgery

          -  No abnormality of the cornea, lens, or central retina

          -  Investigator willing to observe the IXT untreated for 3 years unless specific criteria
             for deterioration are met.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel E Neely, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glick Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glick Eye Institute, Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2015</study_first_submitted>
  <study_first_submitted_qc>June 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2015</study_first_posted>
  <results_first_submitted>April 20, 2017</results_first_submitted>
  <results_first_submitted_qc>October 22, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 30, 2017</results_first_posted>
  <last_update_submitted>October 22, 2017</last_update_submitted>
  <last_update_submitted_qc>October 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Daniel E. Neely</investigator_full_name>
    <investigator_title>Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>IXT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exotropia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CIAO Therapy</title>
          <description>Intervention with wearing 3-hour daily CIAO therapy glasses
CIAO therapy Amblyz glasses: 3-hour CIAO Therapy Amblyz glasses</description>
        </group>
        <group group_id="P2">
          <title>Observation</title>
          <description>To observe as one kind of standard care for IXT.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CIAO Therapy</title>
          <description>Intervention with wearing 3-hour daily CIAO therapy glasses
CIAO therapy Amblyz glasses: 3-hour CIAO Therapy Amblyz glasses</description>
        </group>
        <group group_id="B2">
          <title>Observation</title>
          <description>To observe as one kind of standard care for IXT.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.7" spread="1.94"/>
                    <measurement group_id="B2" value="6.24" spread="4.17"/>
                    <measurement group_id="B3" value="5.91" spread="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IXT Control Score at distance</title>
          <description>IXT control score: referring to the Pediatric eye disease investigator group (PEDIG).
PEDIG scale of control for IXT 1-5 is defined as the following:
5 = Constant exotropia
4 = exotropia &gt; 50% of the 30-sec period before dissociation
3 = exotropia &lt; 50% of the 30-sec period before dissociation
2 = No exotropia unless dissociated, recovers in &gt; 5 sec
1 = No exotropia unless dissociated, recovers in 1-5 sec
0 = No exotropia unless dissociated, recovers in &lt; 1 sec (phoria)
Not Applicable = No exotropia present</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4" spread=".71"/>
                    <measurement group_id="B2" value="2.67" spread=".57"/>
                    <measurement group_id="B3" value="3.5" spread=".92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Composite Measure of IXT Control Score</title>
        <description>IXT control score: referring to the Pediatric eye disease investigator group (PEDIG).
PEDIG scale of control for IXT 1-5 is defined as the following:
5 = Constant exotropia 4 = exotropia &gt; 50% of the 30-sec period before dissociation 3 = exotropia &lt; 50% of the 30-sec period before dissociation 2 = No exotropia unless dissociated, recovers in &gt; 5 sec
1 = No exotropia unless dissociated, recovers in 1-5 sec 0 = No exotropia unless dissociated, recovers in &lt; 1 sec (phoria) Not Applicable = No exotropia present</description>
        <time_frame>12 weeks; 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CIAO Therapy</title>
            <description>Intervention with wearing 3-hour daily CIAO therapy glasses
CIAO therapy Amblyz glasses: 3-hour CIAO Therapy Amblyz glasses</description>
          </group>
          <group group_id="O2">
            <title>Observation</title>
            <description>To observe as one kind of standard care for IXT.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Composite Measure of IXT Control Score</title>
          <description>IXT control score: referring to the Pediatric eye disease investigator group (PEDIG).
PEDIG scale of control for IXT 1-5 is defined as the following:
5 = Constant exotropia 4 = exotropia &gt; 50% of the 30-sec period before dissociation 3 = exotropia &lt; 50% of the 30-sec period before dissociation 2 = No exotropia unless dissociated, recovers in &gt; 5 sec
1 = No exotropia unless dissociated, recovers in 1-5 sec 0 = No exotropia unless dissociated, recovers in &lt; 1 sec (phoria) Not Applicable = No exotropia present</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Amblyopia</title>
        <description>It is defined when visual acuity between two eyes equal or over 2 logMAR lines.</description>
        <time_frame>3 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CIAO Therapy</title>
            <description>Intervention with wearing 3-hour daily CIAO therapy glasses
CIAO therapy Amblyz glasses: 3-hour CIAO Therapy Amblyz glasses</description>
          </group>
          <group group_id="O2">
            <title>Observation</title>
            <description>To observe as one kind of standard care for IXT.</description>
          </group>
        </group_list>
        <measure>
          <title>Amblyopia</title>
          <description>It is defined when visual acuity between two eyes equal or over 2 logMAR lines.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3MO</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CIAO Therapy</title>
          <description>Intervention with wearing 3-hour daily CIAO therapy glasses
CIAO therapy Amblyz glasses: 3-hour CIAO Therapy Amblyz glasses</description>
        </group>
        <group group_id="E2">
          <title>Observation</title>
          <description>To observe as one kind of standard care for IXT.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daniel Neely</name_or_title>
      <organization>Indiana University</organization>
      <phone>3172741214</phone>
      <email>deneely@iupui.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

